Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008025 | 0.88 | NLRP3 (0.44) | MEN1KMT2ATSHRNPSR1HPGD | |
| SCHEMBL2080446 | 0.88 | CES2 (0.49) | MEN1KMT2ATSHRNPSR1CES2 | |
| SCHEMBL2199535 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPSR1HPGDMAPT | |
| SCHEMBL25204030 | 0.85 | CES2 (0.53) | MEN1KMT2ATSHRNPSR1HPGD | |
| SCHEMBL3718401 | 0.85 | MAP2K1 (0.43) | MEN1KMT2ATSHRNPSR1HPGD | |
| SCHEMBL15265331 | 0.85 | MIF (0.45) | MEN1KMT2ANPSR1HPGDMAPK1 | |
| SCHEMBL10604420 | 0.84 | KMT2A (0.54) | MEN1KMT2ATSHRNPSR1HPGD | |
| SCHEMBL28667424 | 0.83 | MAPT (0.50) | MEN1KMT2ATSHRNPSR1HPGD | |
| SCHEMBL2645532 | 0.82 | NPSR1 (0.45) | MEN1KMT2ANPSR1HPGDCES2 | |
| SCHEMBL30071516 | 0.82 | GAA (0.47) | MEN1KMT2ANPSR1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230123591-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-11466018-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3277673-B1 | TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210130361-A1 | TGF-ß INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-10822337-B2 | TGF-β inhibitorC | RIGEL PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180086764-A1 | TGF-ß Inhibitors | MIDCAP FINANCIAL TRUST | 2018-03-29 | — | — | US | disclosed |
| EP-3277673-A1 | TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016160881-A1 | TGF-β INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8372851-B2 | Pyrazolo pyrimidines as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-1948663-B1 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-1948663-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048066-A2 | PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227508-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | MEN1 2625/4885KMT2A 2866/4885TSHR 1236/4885 |
| US-10822337-B2 | TGF-β inhibitorC | TGFBR1, TGFBR2, TGFB1 | MEN1 2194/4885KMT2A 2646/4885TSHR 1814/4885 |
| US-11466018-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | MEN1 2625/4885KMT2A 2866/4885TSHR 1236/4885 |
| US-20100130488-A1 | Pyrazolo-Pyrimidines as Casein Kinase II (CK2) Modulators | CSNK1A1, CSNK2A1, CSNK2A2 | MEN1 4587/4885KMT2A 1688/4885TSHR 1210/4885 |
| US-20210130361-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | MEN1 2534/4885KMT2A 2918/4885TSHR 1240/4885 |
| US-20180086764-A1 | TGF-ß Inhibitors | TGFBR1, TGFBR2, TGFB1 | MEN1 2534/4885KMT2A 2918/4885TSHR 1240/4885 |
| US-20230123591-A1 | TGF-ß INHIBITORS | TGFBR1, TGFBR2, TGFB1 | MEN1 2534/4885KMT2A 2918/4885TSHR 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.